Hypotensive action of luohuo capsule and its effect on plasma adrenal medullin and tissue factor pathway inhibitor.
- Author:
Xiang-dong YU
1
;
Wen-quan ZHOU
;
Ling CUI
Author Information
- Publication Type:Clinical Trial
- MeSH: Adrenomedullin; Adult; Aged; Antihypertensive Agents; therapeutic use; Capsules; Drugs, Chinese Herbal; therapeutic use; Female; Humans; Hypertension; drug therapy; Lipoproteins; blood; Male; Middle Aged; Peptides; blood; Phytotherapy; Single-Blind Method
- From: Chinese Journal of Integrated Traditional and Western Medicine 2003;23(9):668-672
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo study the therapeutic effect of Luohuo Capsule (LHC) clinically.
METHODSClinical trial on 90 patients were carried out adopting randomized, stratified, single-blinded and positive drug controlled method, by divided patients into the treated group (n = 60) and the control group (n = 30). The treated group was treated with LHC, which was mainly consisted of Leech, Radish seed, Water-plantain Tuber, Chuanxiong, etc. The control group was treated with Beijing Hypotensive. No. 0. The therapeutic course was 4 weeks. The diagnosis and efficacy evaluation were in accord with corresponding national standards, using the indexes including safety, clinical symptoms, blood pressure, hemorrheologic parameters, blood lipid, adrenal medullin (AdM) and plasma tissue factor pathway inhibitor (TFPI).
RESULTSThe total effective rate of LHC in lowering blood pressure in the treated group and the control group was 85.00% and 86.67% respectively, comparison of them showed no significant difference (P = 0.915). Most of the improvement of clinical symptoms in the treated group were better than those in the control group (P < 0.05 or P < 0.01). LHC could also improve the hemorrheologic status (P < 0.01), alleviate the blood lipids disorder (P < 0.05), and adjust AdM and TFPI (P < 0.05).
CONCLUSIONLHC is safe in treating hypertension grade I and II with no adverse reaction.
